Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated March 5, 2026, announces the publication of the Annual Report for the fiscal year ended December 31, 2025. GSK is a global biopharma company headquartered in London, United Kingdom.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely as a notification of the Annual Report's availability rather than a financial results release.
Material Changes
No material financial changes or comparative period data are disclosed in this filing. The document references the submission of the full Annual Report 2025 to the UK Financial Conduct Authority's National Storage Mechanism (NSM).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that this announcement is not a substitute for reading the Annual Report 2025 in full.
Investor Verification Checklist
- Verify the full Annual Report 2025 on the company website (https://annualreport.gsk.com) or the FCA NSM for detailed financial data.
- Confirm the date of the Annual General Meeting (AGM) 2026 via the AGM Notice, expected to be sent around March 25, 2026.
- Review the unedited full text of the Annual Report for compliance with FCA Disclosure Guidance and Transparency Rules (DTRs).